Imunoterapia Ativa Específica e imunoquimioterapia Adotiva em Tumores Experimentais. Ação da “interleukin-2”
DOI:
https://doi.org/10.32635/2176-9745.RBC.1982v29n1.3520Keywords:
Immunotherapy, Active, Interleukin-2Abstract
Proteíns from plasmatic membrana of tumor cells were obtained by blistering the membrana of tumors cells and used as tumor antigen. In a syngenelc system, the inoculation of the prepared antigen resulted in 80% protect of mice against tumor challenge. Eradication of established tumors was obtained with the same antigen material. Adoptive specific immunotherapy by the inoculation of spieen cells of immune mice or Cyclophosphamide alone were ineffective against established syngenelc tumor Addptive chemoimmunotherapy-spleen cells of immune mice + Cyclophosphamide eradicated 80% of established syngeneic tumor. Considering the possibility of similar procedures being employed in patients, we are trying. in mice bearing syngeneic tumor to change the spleen lymphocyte injection by "lnterleukin-2" produced "in vitro" with macrophage -i- T helper and Con A. Preliminary data on established tumors results in a very clear delay of tumor growth as compared to the control group. We are now trying to prepare pure "lnterleukin-2" produced with tumor specific antigen.
Downloads
References
ABREU, L.A. & ABREU, R.R, - Effect of cyclophosphamide on sérum ceruloplasmin oxidase activity In sarcoma bearing rats. Arch. Geschwulstforsch 51: 394-397 (1981).
BERENDT. M.J, & NORTH, R.J.- T-cell-mediated suppression of antitumor ímmunítv. An explanatíon of Progressive growth of a immunogenic tumor. J. Exp. Med. 151: 69-80 (1980). DOI: https://doi.org/10.1084/jem.151.1.69
CALABRESI, P & PARKSJR , E.R.- Alkylating agents, antimetabolites, hormones, and others antiprollferating agents tn: The pharmacological basis of therapeutics. L.S. Goodman & A, Gilman. eds., 5th ed., Mac Miilan, New York. pp 1254-1307 (1975).
CASTRO FARIA, H., GRYNBERG, N.F, SOUZA. AS. R. & GOMES, R M. - Eradication of established munne tumor with plasma membrane vesicles and Corynebacteríum granutosum fractíon. 4th Int, Congress of Immunology. Raris, abstr 10.5 11 (1980).
CHEEVER, M.A., GREENBERG, P.P. & FEFER, A. — Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 125: 711 (1980). DOI: https://doi.org/10.4049/jimmunol.125.2.711
FARIA, H C., PREZA, P., MARINHO, R, & BASTOS, V.C. — Specific resistence elicited in mice or rats by injection of plasmatic membrana from syngeneic tumor cells obtained by a nevy technique. XII Congresso Int. del Cancer, abstr, 1/22 Buenos Aires (1978).
FEFER, A. — Tumor Immunotherapy. In.-Antineoplastic and Immunosuppressive agents I. A.C. Sartorelli and D.G. Johns, eds., Springer-Verlag. Berlin, Heidelberg, New York, pp, 528-554 (1974). DOI: https://doi.org/10.1007/978-3-642-65678-1_26
GOMES, R M., PREZA, P., BASTOS, V.C., COELHO, M.G.P., KOVARY, K. & CASTRO FARIA, H. – Controle do crescimento do tumor experimental, 1. Proteção do hospedeiro por inoculação prévia da fração de membrana plasmática de célula tumoral. Rev. Bras. de Pesquisas Méd. e Biol. 711: 229-236 (1978).
GRONVIK, KrO. &ANDERSON.J.- The role of T cell growth stimulating factors in T cell triggering. Immunol. Rev. 51: 35-57 (1980). DOI: https://doi.org/10.1111/j.1600-065X.1980.tb00316.x
HARDT, C., HEEG, K., PFIZENMAIER, K. ROLLENGHOFF, M. & WAGNER. H. - Regulation of cytotoxic T lymphocyte (CTL) responses in vivo: Functional activity of Ly 1 T helper cell derived lnterleukin-2 (IL-2) is controlled byT cell derived IL-2 inhibitor, 4th Int. Congress of Immunology, abstr. 6.4.05, Paris (1980).
WAGNER. H., HARDT, C., HEEG, K. PFIZENMAIER, K., SOLBACH, W., BARTLETT R., STOCKINGER, H & ROLLINGHOF, M, T-T cell interactions, during cytotoxic T lymphocyte .(CTL) responses; T cell derived helper fator (lnterleukin-2) as a probe to analyse CTL responsiveness and thynic maturation of CTL progenitors. Immunol. Rev. 51: 215-255 (1980). DOI: https://doi.org/10.1111/j.1600-065X.1980.tb00323.x
WATSON, J. & MOCHIZUKI, D, - interleukin-2; A class of T cell growth factors. — Immunol, Rev. 51 ;257-278 (1980). DOI: https://doi.org/10.1111/j.1600-065X.1980.tb00324.x
